about
The randomised Complete versus Lesion-only PRimary percutaneous coronary Intervention Trial: Cardiovascular Magnetic Resonance imaging substudy (CvLPRIT-CMR)Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation.Pharmacokinetics of linagliptin in subjects with hepatic impairmentA randomised controlled trial of six weeks of home enteral nutrition versus standard care after oesophagectomy or total gastrectomy for cancer: report on a pilot and feasibility study.Complete Versus Lesion-Only Primary PCI: The Randomized Cardiovascular MR CvLPRIT SubstudyDabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.Evaluation of a self-administered oral glucose tolerance testCluster randomised trial of a tailored intervention to improve the management of overweight and obesity in primary care in EnglandEvaluation of a tailored intervention to improve management of overweight and obesity in primary care: study protocol of a cluster randomised controlled trial.Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.Indirect bioequivalence assessment using network meta-analyses.Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study.Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all formulations.Statistical reporting of clinical pharmacology research.How publication guidelines for clinical pharmacology trials may help to accelerate knowledge transfer.Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.Interpretation of general measures of distribution kinetics in terms of a mammillary compartmental model.Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial.Sensitivity of empirical metrics of rate of absorption in bioequivalence studiesAssessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjectsEvaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteersThe oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitusEffect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteersEffect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tabletsThe potential of the estimands framework for clinical pharmacology trials: Some discussion pointsSample size determination in bioequivalence studies using statistical assurance
P50
Q27000396-670E3F23-B5F2-41A6-A426-9E658E5CAC14Q33901132-0EDB3664-A228-4BBD-8A55-74B4238287B2Q36087961-90ACFD3B-9155-4847-9910-7D466BEB00BEQ36304063-99C1D080-47B7-480E-B7C8-B52DC04AF462Q36378795-8C7EA461-BA59-44D7-9D0A-00A88F187192Q36791747-9C5C85A2-BB73-4327-BF14-7C0CA9604668Q36868182-E9750E0C-F4F1-4EFB-8390-7DBB5EA82CFBQ36945361-661596EB-20AC-48B6-B8B6-03063503DF44Q37681236-42F5A692-A472-44F9-BE60-93023550746BQ42656227-610AFBD8-A6FD-4ED2-8695-46D09171D6CBQ42831059-D219252B-CFBE-4E10-9E62-425C705A430BQ45288034-C869140D-4E51-4370-AB01-A4D4FA85AB01Q45954849-E5593791-7D0F-4E8B-B001-13ECA770BF26Q46183977-5ED4C5C2-AAB2-488A-B77B-CE40EE494003Q46650436-051FE68C-9BE8-4E04-BAD4-E61B64E5B211Q48099983-9812092D-356A-4013-BACE-BC6BE58B0815Q50088331-E013B6EE-C6EF-4B29-A216-7EB136F73B38Q50468289-08A1343E-0CB5-456F-9629-062331D4531EQ51444165-EB8CD348-05EB-40E1-88C7-9B487B5B708EQ51532199-18DDEA9E-2626-4685-BAAB-2A18E6598CF0Q54704673-DBF8FC3D-6204-474D-B443-D394666A57D8Q73975566-4124AD14-78E7-4D98-A792-D62363506D78Q82490323-8CFC85A7-C7CA-4B2F-A404-BE5B126A1100Q83459939-6CF37968-323F-4304-B250-8C01024F1096Q83478451-1718B25B-7255-4522-B5EC-EFE65F75E586Q84036120-1A6219EA-CD6E-4DE4-A53A-54C56ED07401Q84358203-7654723B-1DF0-4AE2-8B87-20FAC2024F8AQ87730179-EE2632C7-F8B4-4EBB-A5D8-903D90683582Q89587763-CC4527B4-1341-4431-903A-D11000CA33ACQ91651553-B80AAFB6-3DAA-4DB7-8ECD-161A05A6CCA3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Arne Ring
@ast
Arne Ring
@en
Arne Ring
@es
Arne Ring
@nl
type
label
Arne Ring
@ast
Arne Ring
@en
Arne Ring
@es
Arne Ring
@nl
prefLabel
Arne Ring
@ast
Arne Ring
@en
Arne Ring
@es
Arne Ring
@nl
P106
P1153
24825606000
P31
P496
0000-0002-4324-5820